PE20240935A1 - Compuestos de imidazopiridazina inhibidores de il-17 - Google Patents
Compuestos de imidazopiridazina inhibidores de il-17Info
- Publication number
- PE20240935A1 PE20240935A1 PE2024000594A PE2024000594A PE20240935A1 PE 20240935 A1 PE20240935 A1 PE 20240935A1 PE 2024000594 A PE2024000594 A PE 2024000594A PE 2024000594 A PE2024000594 A PE 2024000594A PE 20240935 A1 PE20240935 A1 PE 20240935A1
- Authority
- PE
- Peru
- Prior art keywords
- alkyl
- cycloalkyl
- unsubstituted
- substituted
- fluorine atoms
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Rheumatology (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Pain & Pain Management (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163248566P | 2021-09-27 | 2021-09-27 | |
| US202163273422P | 2021-10-29 | 2021-10-29 | |
| US202263367546P | 2022-07-01 | 2022-07-01 | |
| PCT/US2022/077001 WO2023049887A1 (en) | 2021-09-27 | 2022-09-26 | Imidazopyridazine il-17 inhibitor compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20240935A1 true PE20240935A1 (es) | 2024-04-30 |
Family
ID=83692741
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2024000594A PE20240935A1 (es) | 2021-09-27 | 2022-09-26 | Compuestos de imidazopiridazina inhibidores de il-17 |
Country Status (16)
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2022349687A1 (en) | 2021-09-27 | 2024-05-16 | Janssen Pharmaceutica Nv | Imidazopyridazine il-17 inhibitor compounds |
| US12024507B2 (en) | 2021-10-25 | 2024-07-02 | Terns Pharmaceuticals, Inc. | Compounds as GLP-1R agonists |
| TW202430165A (zh) | 2022-12-02 | 2024-08-01 | 丹麥商理奧藥品公司 | Il-17之小分子調節劑 |
| AU2024213283A1 (en) * | 2023-01-30 | 2025-08-14 | Dice Alpha, Inc. | Benzimidazole and aza-benzimidazole based il-17a modulators and uses thereof |
| EP4688156A1 (en) * | 2023-03-28 | 2026-02-11 | Janssen Pharmaceutica NV | Lactam-containing imidazopyridazine il-17 inhibitor compounds |
| PE20252787A1 (es) | 2023-04-07 | 2025-12-22 | Terns Pharmaceuticals Inc | Combinacion que comprende un agonista de thr-beta y un agonista de glp-1r para su uso en el tratamiento de un trastorno hepatico o una enfermedad cardiometabolica |
| WO2024215597A1 (en) * | 2023-04-11 | 2024-10-17 | Dice Alpha, Inc. | Substituted 6-imidazopyridazine il-17a modulators and uses thereof |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111601799B (zh) * | 2018-01-15 | 2023-06-09 | Ucb生物制药有限责任公司 | 作为Il-17调节剂的稠合咪唑衍生物 |
| TWI752400B (zh) * | 2019-01-07 | 2022-01-11 | 美商美國禮來大藥廠 | Il-17a抑制劑 |
| GB201909190D0 (en) | 2019-06-26 | 2019-08-07 | Ucb Biopharma Sprl | Therapeutic agents |
| CN112341450B (zh) * | 2019-08-09 | 2022-05-17 | 成都先导药物开发股份有限公司 | 一种免疫调节剂 |
| WO2021098844A1 (zh) * | 2019-11-20 | 2021-05-27 | 成都先导药物开发股份有限公司 | 一种免疫调节剂 |
| WO2021170627A1 (en) * | 2020-02-25 | 2021-09-02 | UCB Biopharma SRL | Difluorocyclohexyl derivatives as il-17 modulators |
| JP7664947B2 (ja) | 2020-04-30 | 2025-04-18 | ヤンセン ファーマシューティカ エヌ.ベー. | Il-17の調節因子としてのイミダゾリダジン |
| WO2023025783A1 (en) | 2021-08-23 | 2023-03-02 | Leo Pharma A/S | Small molecule modulators of il-17 |
| AU2022349687A1 (en) | 2021-09-27 | 2024-05-16 | Janssen Pharmaceutica Nv | Imidazopyridazine il-17 inhibitor compounds |
| CN116143777A (zh) | 2021-11-04 | 2023-05-23 | 四川海思科制药有限公司 | 一种可抑制il-17a的杂环化合物及其用途 |
-
2022
- 2022-09-26 AU AU2022349687A patent/AU2022349687A1/en active Pending
- 2022-09-26 UY UY0001039958A patent/UY39958A/es unknown
- 2022-09-26 JP JP2024518884A patent/JP2024536869A/ja active Pending
- 2022-09-26 IL IL311751A patent/IL311751A/en unknown
- 2022-09-26 PE PE2024000594A patent/PE20240935A1/es unknown
- 2022-09-26 TW TW111136301A patent/TW202330530A/zh unknown
- 2022-09-26 WO PCT/US2022/077001 patent/WO2023049887A1/en not_active Ceased
- 2022-09-26 CA CA3233408A patent/CA3233408A1/en active Pending
- 2022-09-26 KR KR1020247013352A patent/KR20240082369A/ko active Pending
- 2022-09-26 US US17/935,360 patent/US12173007B2/en active Active
- 2022-09-26 EP EP22790174.1A patent/EP4408847A1/en active Pending
- 2022-09-26 MX MX2024003772A patent/MX2024003772A/es unknown
-
2024
- 2024-03-14 DO DO2024000051A patent/DOP2024000051A/es unknown
- 2024-03-22 CO CONC2024/0003723A patent/CO2024003723A2/es unknown
- 2024-03-25 CL CL2024000867A patent/CL2024000867A1/es unknown
- 2024-03-26 JO JOJO/P/2024/0059A patent/JOP20240059A1/ar unknown
- 2024-10-04 US US18/906,207 patent/US20250109137A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| TW202330530A (zh) | 2023-08-01 |
| JOP20240059A1 (ar) | 2024-03-26 |
| WO2023049887A1 (en) | 2023-03-30 |
| CO2024003723A2 (es) | 2024-04-18 |
| JP2024536869A (ja) | 2024-10-08 |
| KR20240082369A (ko) | 2024-06-10 |
| UY39958A (es) | 2023-04-28 |
| US20230143050A1 (en) | 2023-05-11 |
| AU2022349687A1 (en) | 2024-05-16 |
| MX2024003772A (es) | 2024-06-19 |
| DOP2024000051A (es) | 2024-11-15 |
| CL2024000867A1 (es) | 2024-09-23 |
| CA3233408A1 (en) | 2023-03-30 |
| EP4408847A1 (en) | 2024-08-07 |
| US20250109137A1 (en) | 2025-04-03 |
| IL311751A (en) | 2024-05-01 |
| US12173007B2 (en) | 2024-12-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20240765A1 (es) | Compuestos para la inhibicion de nlrp3 y usos de estos | |
| CL2021002883A1 (es) | Moduladores de thr-ß y métodos de uso de estos | |
| CO6251201A2 (es) | Composiciones y metodos para el tratamiento de3 enfermedades y desordenes oftalmicos | |
| UY39029A (es) | Uso de compuestos de aminopropionato sustituido en el tratamiento de la infección por sars-cov-2 | |
| CL2020001871A1 (es) | Dihidrobenzofurano e inden analogos como inhibidores de sarcómero cardíaco. | |
| AR054560A1 (es) | Espiropiperidina como inhibidores de beta-secretasa para el tratamiento de la enfermedad de alzheimer | |
| AR059621A1 (es) | Acidos 4- fenil- tiazol-5- carboxilicos y amidas de acidos 4- fenil- tiazol5 carboxilicos como inhibidores de la plk1 | |
| PE20181093A1 (es) | Compuestos heterociclicos y usos de los mismos | |
| AR084032A1 (es) | Compuesto biciclico | |
| AR085327A1 (es) | Inhibidores del virus de la hepatitis c | |
| PE20151951A1 (es) | Heteroarildihidropirimidinas unidas por puentes en 6 para el tratamiento y la profilaxis de infeccion por el virus de la hepatitis b | |
| AR100810A1 (es) | Inhibidores de fosfatidilinositol 3-quinasa | |
| CR10034A (es) | Derivados de oxadiazol | |
| PE20142081A1 (es) | Inhibidores de quinurenina-3-monooxigenasa, composiciones farmaceuticas y metodo de uso de los mismos | |
| MX2015014746A (es) | Derivados de dolastatina 10 y auristatinas. | |
| AR098522A1 (es) | Compuesto de triazolo-piridina | |
| AR129378A1 (es) | Compuestos de indolinilo antivirales y usos de estos | |
| MY170822A (en) | Ethynyl derivatives as mglur5 allosteric modulators | |
| MX385276B (es) | Tratamiento para la enfermedad de parkinson | |
| AR128717A1 (es) | Formas sólidas, sales y procesos de preparación de un inhibidor de cdk2 | |
| CL2023003758A1 (es) | Pirimidinil-pirazoles sustituidos como inhibidores de cdk2 | |
| AR087470A1 (es) | Derivados imidazolicos bifenilenicos y composiciones farmaceuticas que los contienen | |
| DOP2024000051A (es) | Compuestos de imidazopiridazina inhibidores de il-17 | |
| PE20210404A1 (es) | Derivados de pirrolo [1,2-b] piridazina | |
| PE20240691A1 (es) | Compuestos moduladores de gcn2 y usos de los mismos |